Cantuzumab mertansine
Cantuzumab mertansine (pronunciation: kan-too-zoo-mab mer-tan-seen) is a monoclonal antibody designed for the treatment of cancer. It is a conjugate drug, meaning it combines two different substances: an antibody and a drug.
Etymology
The name "Cantuzumab mertansine" is derived from the names of its two components. "Cantuzumab" is the name of the monoclonal antibody, and "mertansine" is the name of the drug that is attached to the antibody. The prefix "cantu-" is derived from the Latin word "cantus", meaning "song", and the suffix "-mab" is an abbreviation for "monoclonal antibody". The term "mertansine" is derived from the name of the plant from which the drug is derived, Maytenus senegalensis.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Conjugate drug: A drug that is combined with another substance, such as an antibody, to enhance its effectiveness.
- Maytenus senegalensis: A plant species from which the drug mertansine is derived.
See Also
External links
- Medical encyclopedia article on Cantuzumab mertansine
- Wikipedia's article - Cantuzumab mertansine
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski